You are here:
Publication details
Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI)
Authors | |
---|---|
Year of publication | 2015 |
Type | Article in Periodical |
Magazine / Source | REGENERATIVE MEDICINE |
MU Faculty or unit | |
Citation | |
Doi | http://dx.doi.org/10.2217/RME.14.93 |
Field | Genetics and molecular biology |
Keywords | COPY NUMBER; MOLECULAR CYTOGENETICS; GENOMIC STABILITY; GENE-EXPRESSION; LINES; CULTURE; CRYOPRESERVATION; MUTATIONS; TERATOCARCINOMAS; STANDARDIZATION |
Description | In 2009 the International Stem Cell Banking Initiative (ISCBI) contributors and the Ethics Working Party of the International Stem Cell Forum published a consensus on principles of best practice for the procurement, cell banking, testing and distribution of human embryonic stem cell (hESC) lines for research purposes [1], which was broadly also applicable to human induced pluripotent stem cell (hiPSC) lines. Here, we revisit this guidance to consider what the requirements would be for delivery of the early seed stocks of stem cell lines intended for clinical applications. The term ‘seed stock’ is used here to describe those cryopreserved stocks of cells established early in the passage history of a pluripotent stem cell line in the lab that derived the line or a stem cell bank, hereafter called the ‘repository’. |